Delivery Order SPE2DB22D3501-SPE2DB25FVL91

Award Date 4/29/25
Potential Completion Date 5/20/25
Potential Value $72K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has a ceiling value of $24,038.58 and runs through May 5, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $34,955.36 and runs through April 2, 2025. The contract is a firm fixed-price, delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product, at a firm fixed price. The contract has a ceiling value of $120,192.80 and a completion date of May 20, 2025. This award is not set aside and represents an open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This is a delivery order contract awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for the supply of OCREVUS 300 mg/10 ml vials. The contract is a firm-fixed-price delivery order with a total ceiling value of $46,236.16 and a period of performance through September 30, 2024. Amerisourcebergen, a major pharmaceutical distributor, is the prime contractor for this award. The contract is not designated as a set-aside. This delivery order is likely part of a larger...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a medication, with a ceiling value of $60,096.40 and a period of performance through May 19, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of OCREVUS 300 mg/10 ml vials. The contract has a ceiling value of $69,354.24 and a completion date of August 9, 2024. It is a firm fixed-price delivery order contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription pharmaceutical product. The contract has a value of $115,590.40 and a completion date of September 25, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor, has been awarded this contract to provide the specified medication to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a medication used to treat multiple sclerosis. The contract has a ceiling value of $24,038.58 and is a firm fixed-price contract. It was awarded on April 10, 2025, with a completion date of May 1, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $120,192.80 firm fixed-price contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $115,590.40 fixed-price contract is for the supply of OCREVUS 300 mg/10 ml vials, a specialty medication. The contract has a ceiling value of $115,590.40 and an ultimate completion date of September 3, 2024. This order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FVL91
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $72,115.74, is for the delivery of OCREVUS 300 mg/10 ml vials over a performance period ending on May 20, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle through December 2026. The contract is not set aside and is awarded on a firm fixed-price basis.

Generated 8/3/25, 1:10 AM